Cambridge, UK – A groundbreaking study spearheaded by researchers at the University of Cambridge has delivered a profoundly reassuring message to women battling breast cancer who also carry specific inherited mutations in the BRCA1 and BRCA2 genes. For years, these women have been offered surgery to remove their ovaries and fallopian tubes, known as bilateral salpingo-oophorectomy (BSO), primarily to mitigate their significantly elevated risk of ovarian cancer. Now, for the first time on a large scale, this procedure has been definitively linked to a substantial reduction in the risk of early death from any cause, including cancer, without introducing serious long-term side-effects.
Published today in the prestigious journal The Lancet Oncology, the findings represent a pivotal moment in the management of hereditary breast and ovarian cancer syndromes. They provide critical evidence supporting BSO not just as a preventative measure against ovarian cancer, but as a life-extending intervention for those already diagnosed with breast cancer.
The Imperative of Prevention: Understanding BRCA and Ovarian Cancer Risk
Women identified with pathogenic variants in the BRCA1 and BRCA2 genes face a lifetime risk of developing breast cancer that can be as high as 85%, and an ovarian cancer risk ranging from 15% to 60%, significantly higher than the general population. Given the aggressive nature and often late detection of ovarian cancer, preventative strategies have long been a cornerstone of care for these high-risk individuals.
The medical community has, for some time, recommended prophylactic BSO to drastically lower the risk of ovarian cancer. Specifically, guidelines suggest this surgery between the ages of 35 and 40 years for BRCA1 carriers, and between 40 and 45 years for BRCA2 carriers, aligning with the typical onset ages of ovarian cancer in these genetic subgroups. Previous research has indeed demonstrated that BSO can reduce the risk of developing ovarian cancer by an impressive 80%.
However, despite these clear benefits, BSO presents a significant trade-off: it induces surgical menopause, removing the body’s primary source of oestrogen at a relatively early age. This abrupt hormonal shift can lead to a cascade of menopausal symptoms, from hot flashes and mood disturbances to bone density loss. For BRCA1 and BRCA2 carriers with a prior history of breast cancer, the situation is particularly complex. Many breast cancer treatments are hormone-sensitive, meaning hormone replacement therapy (HRT) – often used to manage menopausal symptoms – may be contraindicated due to concerns about stimulating cancer recurrence. This leaves a significant population of women facing surgical menopause without the conventional support for its symptoms, raising concerns about their overall quality of life and long-term health. The full impact of BSO on the holistic health and survival of BRCA1 and BRCA2 carriers, particularly those who have already faced a breast cancer diagnosis, remained a crucial unanswered question.
Overcoming Ethical Barriers: A Novel Research Approach
Traditionally, the ‘gold standard’ for evaluating the efficacy and safety of medical interventions is a randomised controlled trial (RCT). In an RCT, participants are randomly assigned to either receive the intervention or a control (e.g., no intervention or a placebo), allowing researchers to isolate the effects of the treatment. However, for a procedure like BSO in high-risk BRCA carriers, an RCT would be ethically untenable. Randomly assigning some women to not receive BSO would knowingly place them at a substantially greater, and avoidable, risk of developing a life-threatening ovarian cancer, a scenario deemed unacceptable by medical ethics boards.
To circumvent this ethical dilemma, the Cambridge research team, in a pioneering collaboration with the National Disease Registration Service (NDRS) within NHS England, adopted an innovative approach. They leveraged the vast, meticulously curated repositories of electronic health records and genetic testing data from NHS laboratories. This rich dataset allowed them to conduct a robust, large-scale observational study, providing invaluable insights into the real-world long-term outcomes of BSO among BRCA1 and BRCA2 pathogenic variant (PV) carriers who had previously been diagnosed with breast cancer. This methodology, while not an RCT, provided the most comprehensive and ethical means to address the pressing clinical questions surrounding BSO.
Unpacking the Data: Significant Survival Gains and No Adverse Effects
The study cohort comprised a substantial group of 3,400 women, each carrying one of the cancer-causing BRCA1 or BRCA2 variants and having a history of breast cancer. This group was almost evenly split, with approximately 1,700 women for each variant. Within this cohort, a significant proportion had undergone BSO: around 850 of the BRCA1 carriers and 1,000 of the BRCA2 carriers. The researchers meticulously tracked the health outcomes of these women over a median follow-up period of 5.5 years, analysing their survival rates and incidence of various health conditions.
The results were compelling and unequivocally positive. Women who underwent BSO were found to be approximately half as likely to die from cancer or any other cause during the follow-up period compared to those who did not have the surgery. This profound reduction in early mortality underscores the significant, holistic survival benefit conferred by the procedure.
A deeper dive into the data revealed variant-specific differences in the magnitude of this benefit. While both groups experienced substantial gains, the reduction in early death was more pronounced among BRCA2 carriers, who saw a remarkable 56% decrease in mortality risk. BRCA1 carriers also benefited significantly, with a 38% reduction. Beyond overall survival, the study also identified another crucial advantage: women who underwent BSO were at around a 40% lower risk of developing a second primary cancer, further highlighting the procedure’s broad protective effects.
While acknowledging the inherent limitations of an observational study – meaning it’s "impossible to say with 100% certainty that BSO causes this reduction" – the research team emphasized that the cumulative weight of the evidence points "strongly towards this conclusion." The consistency of the findings across various analyses strengthens the causal inference.
Crucially, the study also addressed the long-standing concerns about potential negative health consequences associated with surgical menopause. In a significant finding that contrasts with some previous studies on BSO in the general population, the Cambridge researchers found no link between BSO and an increased risk of long-term health issues such as heart disease, stroke, or depression within this specific high-risk cohort. This absence of adverse systemic effects provides immense reassurance to both patients and clinicians, suggesting that for BRCA1/2 breast cancer survivors, the benefits of BSO far outweigh any previously conjectured risks of early menopause.
Expert Commentary and Reassurance for Patients
The publication of these findings has been met with significant enthusiasm from the research team and the wider medical community.
Hend Hassan, the study’s first author and a PhD student at the Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, and Wolfson College, Cambridge, articulated the study’s profound implications: "We know that removing the ovaries and fallopian tubes dramatically reduces the risk of ovarian cancer, but there’s been a question mark over the potential unintended consequences that might arise from the sudden onset of menopause that this causes." She continued, "Reassuringly, our research has shown that for women with a personal history of breast cancer, this procedure brings clear benefits in terms of survival and a lower risk of other cancers without the adverse side effects such as heart conditions or depression." Her comments highlight the dual reassurance provided by the study: confirming survival benefits while simultaneously dispelling fears about common long-term health concerns.
Professor Antonis Antoniou, from the Department of Public Health and Primary Care, served as the study’s senior author. He underscored the immediate clinical relevance of the findings: "Our findings will be crucial for counselling women with cancer linked to one of the BRCA1 and BRCA2 variants, allowing them to make informed decisions about whether or not to opt for this operation." This statement speaks to the core purpose of such research – to empower patients with evidence-based information that supports shared decision-making with their healthcare providers.
Professor Antoniou, who also directs the Cancer Data-Driven Detection programme, further praised the methodology: "The study also highlights the power of exceptional NHS datasets in driving impactful, clinically relevant research." This commendation acknowledges the invaluable contribution of the NHS’s comprehensive and well-maintained health records, demonstrating their potential as a powerful tool for public health research that directly translates into improved patient care.
Addressing Health Disparities and Future Directions
While the study delivered overwhelmingly positive news regarding the efficacy and safety of BSO, it also shone a light on concerning disparities in uptake. The analysis revealed that most women undergoing BSO in the study cohort were white. Alarmingly, Black and Asian women were found to be approximately half as likely to have undergone BSO compared to their white counterparts. Furthermore, women residing in less deprived areas were more likely to opt for BSO than those living in the most-deprived categories.
These disparities are a critical concern, as they suggest that the life-saving benefits of BSO are not being equitably distributed across different demographic and socioeconomic groups. Hend Hassan acknowledged this urgent issue, stating, "Given the clear benefits that this procedure provides for at-risk women, it’s concerning that some groups of women are less likely to undergo it. We need to understand why this is and encourage uptake among these women."
Understanding the root causes of these disparities will be a crucial next step. Potential factors could include differences in access to genetic counselling and testing, cultural perceptions of preventative surgery, language barriers, varying levels of trust in healthcare systems, or socioeconomic barriers that impact the ability to pursue preventative interventions. Addressing these issues will require multi-faceted approaches, including targeted outreach, culturally sensitive patient education, improved access to specialist care, and efforts to build trust within underserved communities.
Implications for Clinical Practice and Public Health
The findings of this Cambridge study are set to significantly influence clinical guidelines and patient counselling practices globally. For women with BRCA1/2 mutations who have already been diagnosed with breast cancer, the evidence now strongly supports BSO as a procedure that not only prevents ovarian cancer but also enhances overall survival and reduces the risk of secondary cancers, all without increasing the risk of cardiovascular disease or depression. This comprehensive understanding allows for more confident and informed discussions between clinicians and patients regarding their preventative care strategies.
Moreover, the study’s innovative use of large-scale NHS electronic health records serves as a powerful testament to the potential of real-world data in addressing complex clinical questions where traditional RCTs are not feasible. This methodology could pave the way for similar impactful research across various medical disciplines, leveraging existing health data to improve patient outcomes.
This vital research was generously funded by Cancer Research UK, with additional support provided by the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre. The collaborative spirit and robust funding underscore the commitment to advancing cancer research and patient care.
Looking ahead, the University of Cambridge and Addenbrooke’s Charitable Trust (ACT) are actively fundraising for the Cambridge Cancer Research Hospital, a visionary project designed to revolutionize cancer diagnosis and treatment. This new facility, a partnership with Cambridge University Hospitals NHS Foundation Trust, promises to serve patients across the East of England while fostering groundbreaking research that will impact cancer patients not only across the UK but worldwide. The insights gleaned from studies like this one highlight the critical need for continued investment in such state-of-the-art facilities and research initiatives to translate scientific discovery into tangible improvements in human health and survival. The journey to conquer cancer is long, but each breakthrough, especially one offering such profound reassurance and life-extending potential, brings us closer to a future where more lives are saved and enhanced.
About the Author
